Rivaroxaban Data at the American Heart Association’s Scientific Sessions 2008

November 8 - 12, 2008
New Orleans, Louisiana, USA

Data from the phase II ATLAS ACS TIMI 46 study of Xarelto® (rivaroxaban) were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.


Monday, November 10, 2008 at 7:00 p.m. CET (6:00 p.m. GMT):
Investor Conference Call - Review of Rivaroxaban Data

with

Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Background Information
About Xarelto®Download (PDF, 465 KB) collect
About Xarelto® Clinical Studies
Download (PDF, 550 KB) collect
About the ATLAS ACS TIMI Trial Program
Download (PDF, 354 KB) collect
About RECORD Studies
Download (PDF, 546 KB) collect
Understanding Acute Coronary Syndrome
Download (PDF, 466 KB) collect
The History of AnticoagulantsDownload (PDF, 506 KB) collect
Understanding Venous Blood ClotsDownload (PDF, 349 KB) collect
Glossary
Download (PDF, 254 KB) collect



Abstract on Rivaroxaban presented at the American Heart Association's Scientific Sessions 2008

Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial

Last updated: January 08, 2014 Copyright © Bayer AG